| Today’s Big NewsJun 12, 2024 |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now. 
|
|
| By Nick Paul Taylor Eli Lilly looks set to make the long-deserted Alzheimer’s disease market a two-horse town—but that may be a good thing for Biogen and Eisai. William Blair analysts are tipping the anticipated approval of a rival anti-amyloid therapy to boost Leqembi by helping raise awareness, although they also see possible risks to the early frontrunner after Lilly waltzed through its advisory committee. |
|
|
|
By Zoey Becker The BIOSECURE Act was officially left off of the National Defense Authorization Act (NDAA), which was the expected first step to the bill's passage. |
By Annalee Armstrong Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration and it’s not exactly a surprise: The New York pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs. |
By Conor Hale Shortly after announcing positive clinical trial data from its pulsed field ablation treatment for irregular heart rhythms, Kardium has more good news to share. |
|
Wednesday, June 26, 2024 | 2pm ET/ 11am PT In this webinar, we outline a patient-centered telehealth genetic counseling model that accelerates time to meet recruitment goals by engaging and recruiting genetically eligible participants. Certified genetic counselors are uniquely qualified to support the development of a multi-phased approach to patient identification and screening, disclose genetic test results, and more. Register now. 
|
|
By Fraiser Kansteiner As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has dealmaking cash to deploy if the right target comes along. |
By Nick Paul Taylor Foresite Capital CEO Jim Tananbaum says we’re in “one of the best biotech investment environments” of his multi-decade career—and has rounded up $900 million to put that belief to the test with a fresh set of big bets. |
By Andrea Park According to a Fierce Pharma Marketing review of the Instagram pages of about two dozen of the world’s biggest drugmakers, as of Wednesday, the majority have acknowledged Pride month in some way. |
By Nick Paul Taylor Ultragenyx and Mereo BioPharma have broken off another piece of brittle bone data, linking their drug candidate to sustained reductions in fracture rates in a midphase clinical trial. |
By Fraiser Kansteiner A federal judge in New Jersey ruled that five of Teva’s patents on the metered dose inhaler for its asthma med ProAir HFA are “improperly listed” in the FDA’s Orange Book. The ruling came in Teva's case against Amneal Pharmaceuticals, which is seeking to launch a generic version of the drug. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report. |
|
|---|
|
|
|
Biotech companies must be able to navigate the complexities of development and approval. Learn how to drive improved speed, quality, predictability, and risk management by making key changes. Download now for exclusive insights. 
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
